Immunology & allergy
Immune system & allergy clinical trials
Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We’re tracking 6,067 recruiting studies in this area right now.
By phase
- Not applicable3,005
- Phase 21,061
- Phase 1794
- Phase 1/Phase 2440
- Phase 3436
- Phase 4233
- Phase 2/Phase 398
Top conditions
- Multiple Sclerosis329
- Multiple Myeloma328
- Asthma194
- Lymphoma178
- Rheumatoid Arthritis131
- Type 1 Diabetes131
- Atopic Dermatitis124
- Systemic Lupus Erythematosus120
- Acute Lymphoblastic Leukemia118
- HIV Infections106
- Chronic Lymphocytic Leukemia96
- Autoimmune Diseases79
- Follicular Lymphoma70
- Rheumatoid Arthritis (RA)68
- Hodgkin Lymphoma64
- Diabetes Mellitus, Type 163
- Leukemia63
- Type 1 Diabetes Mellitus63
Leading sponsors
- National Institute of Allergy and Infectious Diseases (NIAID)97
- Institute of Hematology & Blood Diseases Hospital, China85
- National Cancer Institute (NCI)74
- Assistance Publique - Hôpitaux de Paris65
- AstraZeneca64
- M.D. Anderson Cancer Center58
- Novartis Pharmaceuticals58
- Mayo Clinic50
- City of Hope Medical Center48
- Memorial Sloan Kettering Cancer Center45
Where studies are running
- California498
- Maryland199
- Alabama178
- Florida152
- Arizona150
- Massachusetts117
- New York116
- Texas112
- Illinois82
- Colorado81
Recruiting studies6,067 total
- NCT06934252RecruitingPhase 1
Study of TRB-061 for atopic dermatitis (eczema)
This trial tests an investigational drug called TRB-061 in healthy adults and people with atopic dermatitis (eczema). It aims to see if the drug is safe and how the body processes it. If you have moderate to severe eczema that started at least a year ago, you may be able to join the patient part of the study.
Belconnen, Australian Capital TerritoryAges 18–70 - NCT06936566RecruitingPhase 2
Ruxolitinib for graft-versus-host disease after transplant
This trial tests a drug called ruxolitinib for treating acute graft-versus-host disease (aGVHD), a common complication after a stem cell transplant. It may help control the immune reaction without using high doses of steroids.
Duarte, CaliforniaAges 18 years+ - NCT06940869Enrolling by invitation
Reproductive health registry for rheumatic conditions
This study creates a registry to better understand pregnancy outcomes in people with autoimmune or rheumatic conditions. If you are aged 12 to 55, can become pregnant (or are currently pregnant or planning a pregnancy), and receive care at Duke Health, you may be eligible to join.
Durham, North CarolinaAges 12–55 - NCT06941129RecruitingPhase 1
CAR T-cell therapy for resistant autoimmune diseases
This trial tests a new type of immune therapy called CAR T-cells that target two markers on your B cells (CD19 and BCMA). It is for people with certain autoimmune diseases that have not improved or have come back after standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06934382RecruitingPhase 1
CAR-T cell therapy for relapsed T-cell leukemia or lymphoma
This trial tests a new type of immunotherapy called anti-CD7 CAR-T cells for children and young adults with T-cell acute lymphoblastic leukemia or lymphoma that has come back or not responded to standard treatments. The goal is to see if these specially engineered immune cells can find and destroy cancer cells that carry the CD7 protein.
Philadelphia, PennsylvaniaAges birth–29 years - NCT06936280Recruiting
Type 1 diabetes and diabetes distress study
This trial tests a program for young adults with type 1 diabetes who feel stressed or overwhelmed by their diabetes. The goal is to see if the program can help reduce diabetes distress and improve well-being.
EsbjergAges 18–35 - NCT06940661RecruitingPhase 2
Obinutuzumab for relapsing vasculitis
This trial tests a drug called obinutuzumab to see if it can help people whose vasculitis (inflammation of blood vessels) has come back after previous treatment. It is designed for people with a specific type of vasculitis that affects small blood vessels and is linked to PR3-ANCA antibodies.
ParisAges 18 years+ - NCT06934915RecruitingEarly Phase 1
Prednisone for adults with autism and immune issues
This trial tests if the steroid prednisone can help adults with moderate-to-severe autism who also have signs of immune system problems, like autoimmune disease or inflammation. It might offer a new treatment option for people whose autism is linked to immune activity.
Lexington, MassachusettsAges 18–50 - NCT06941194Recruiting
Preventing wound problems after sarcoma surgery with a special bandage
This trial tests a special negative pressure bandage used after surgery to prevent wound complications in people with high-grade soft tissue sarcoma of the limbs who have had radiation therapy before their operation.
Padova, Italy/PadovaAges 18–99 - NCT06935890RecruitingPhase 4
Long-term effectiveness of jack jumper ant venom therapy
This study checks how well venom immunotherapy for jack jumper ant allergy works years after treatment ends. If you finished 3–5 years of treatment and stopped 1.5 to 5 years ago, you may be able to help.
Adelaide, South AustraliaAges 18 years+ - NCT06940908Recruiting
Living with Guillain-Barré syndrome as a child
This study interviews children who had Guillain-Barré syndrome (GBS) to understand their experiences after recovery. It may help doctors better support young patients with GBS.
Montpellier, OccitanieAges 10–18 - NCT06933134Recruiting
Using a biomarker to guide low-dose rituximab in rheumatoid arthritis
This trial aims to find out if a simple blood test (biomarker) can show whether a lower dose of rituximab will work for people with rheumatoid arthritis. If successful, it could help patients maintain good results with less medicine and fewer side effects.
ToursAges 18 years+ - NCT06940323Recruiting
Pregnancy study for women with chronic conditions
This study tracks pregnant women with certain chronic health conditions (like multiple sclerosis, lupus, or rheumatoid arthritis) and healthy pregnant women as a comparison group. It aims to understand how these conditions and their treatments affect pregnancy, the baby, and breast milk.
San Francisco, CaliforniaAges 18–64 - NCT06939166RecruitingEarly Phase 1
Immune cell therapy for relapsed neurological autoimmune diseases
This trial tests a new type of immune cell therapy (CAR T-cells) that targets CD19 and BCMA proteins on B cells. It is for people with certain neurological autoimmune diseases that have come back or not responded to standard treatments. The goal is to see if this therapy can help control the disease.
TianjinAges 18 years+ - NCT06934200RecruitingPhase 2
Xolair for food allergy in people with high IgE
This study tests if omalizumab (Xolair), an injectable medicine that blocks allergy antibodies, can help people with food allergies tolerate small amounts of their trigger foods. It's for people with high total IgE levels who were not eligible for a related study.
Baltimore, MarylandAges 1–55 - NCT06937320Enrolling by invitationPhase 2
Testing ketone supplements for heart failure with preserved ejection fraction (HFpEF)
This study tests whether a special dietary supplement (ketone esters) can improve exercise ability and heart function in people with a type of heart failure where the heart pumps well but is stiff (HFpEF). You might join if you have stable symptoms, an ejection fraction of 50% or higher, and signs of fluid buildup in the heart.
Durham, North CarolinaAges 18 years+ - NCT06940297RecruitingPhase 2
Dasatinib and quercetin with CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests whether adding two drugs, dasatinib and quercetin, to CAR-T therapy can help people with multiple myeloma that has come back or not responded to past treatments. It aims to make the CAR-T cells work better and reduce side effects.
Rochester, MinnesotaAges 18 years+ - NCT06935084Recruiting
Voice app for asthma management study
This study tests if a voice-controlled smartphone app (like Siri or Alexa) can help people with asthma manage their daily controller medicine better. You might be a good fit if you use a daily asthma inhaler and have a smartphone with a data plan.
The Bronx, New YorkAges 18 years+ - NCT06933277Recruiting
Study of selinexor, bortezomib, and dexamethasone for multiple myeloma
This observational study looks at a three-drug combination (selinexor, bortezomib, and dexamethasone) for people with multiple myeloma that has come back after 1 to 3 prior treatments. It may be an option if you've already tried and not responded to lenalidomide.
FlorenceAges 18 years+ - NCT06932848Recruiting
Curcumin gel for treating oral lichen planus
This trial tests if a curcumin nanogel can help heal painful sores from oral lichen planus compared to a standard corticosteroid gel. If you have this condition, you may be able to join.
BangkokAges 18 years+ - NCT06550427Recruiting
Lymphoma treatment response monitoring with genetic testing
This trial is testing a new way to monitor how well your lymphoma treatment is working. It uses a blood test to look for genetic changes in cancer cells, which may help doctors make better treatment decisions.
TaipeiAges 18 years+ - NCT06700798RecruitingPhase 2
Orelabrutinib plus rituximab vs R-CVP for untreated MZL
This trial tests a new combination of two drugs (orelabrutinib and rituximab) compared to the standard R-CVP chemotherapy for people with newly diagnosed marginal zone lymphoma. The goal is to see which approach works better and has fewer side effects.
Nanchang, JiangxiAges 18 years+ - NCT06805318Recruiting
Job support program for people with MS
This study tests a vocational rehabilitation program designed to help people with multiple sclerosis (MS) keep their jobs. If you have MS and are currently working, this program may help you stay employed.
Rome, LazioAges 18 years+ - NCT06875908Recruiting
Turkish sleep survey test for multiple sclerosis
This study tests a Turkish-language sleep survey for people with multiple sclerosis. It aims to see if the survey is a reliable way to measure sleep problems in MS patients.
Bağcılar, IstanbulAges 18–65
Common questions
- How many immune system & allergy clinical trials are recruiting?
- Clin2 is tracking 6,067 recruiting immunology & allergy studies from the U.S. registry right now, out of 9,197 we cover in this area in total.
- What does “Immune system & allergy” cover here?
- Autoimmune conditions, allergies, and disorders of the body’s immune defenses. We group each study into immune system & allergy based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a immune system & allergy trial near me?
- Use the search to filter immune system & allergy studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.